Cancer-associated fibroblasts (CAFs) 
Introduction
Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths, mainly due to the development of metastases in liver and lung, with a median survival of 2 years 1, 2 . Cancer progression and metastasis is controlled by the tumor microenvironment (TME) and does not depend solely on cancer cells. A dominant component of this TME are the cancer associated fibroblasts (CAFs), residing within the tumor margins or infiltrating the tumor mass and contributing to tumor progression by invasion, angiogenesis and manipulation of the immune response [3] [4] [5] [6] . On the other hand, the pro-tumorigenic role of CAFs in cancer progression has recently been challenged as depletion of CAFs by its general marker, -smooth muscle actin (SMA), led to more invasive tumors, associated with an immunosuppressive T-cell response [7] [8] [9] . This heterogeneity of CAFs raises the question whether we can identify distinct subsets of pro-tumorigenic CAFs for developing stromal cell targeted therapies 10 .
Immune checkpoint inhibitors targeting the cytotoxic T-lymphocyte associated protein-4 (CTLA- 4) and programmed cell death-1 (PD-1) receptors have recently made their way into the clinic, producing substantial clinical benefits. Considering advanced colorectal cancer, the early signals of activity are largely involving microsatellite instable (MSI) tumors 11, 12 . Unfortunately, this still leaves a great need for effective immunotherapies in the majority of CRC. Here, we focused on the immune checkpoint molecule CD70 as a potential new target in CRC. Under normal conditions, CD70, member of the tumor necrosis factor (TNF) family, is only transiently expressed on activated T and B cells.
Instead, constitutive overexpression of CD70 has been described on malignant cells in a range of solid and haematological malignancies 13 . In addition, CD70 expression has been occasionally shown on certain non-immunological stromal cells 14 . Through its receptor, CD27, the overexpression of CD70 can facilitate evasion of the immune system by three important mechanisms: induction of T cell apoptosis, T cell exhaustion and increasing the amount of suppressive regulatory T cells (Tregs) 13, 15 .
In the present study, we are the first to display the expression patterns of CD70 in CRC specimens.
We report that CD70 expression is almost absent from tumor cells but is strongly present on a subset of CAFs. Moreover, CD70
+ CAFs play an important role as predictors for the outcome of CRC patients.
Finally, our results implicate a role of CD70 + CAFs in cancer cell migration and Treg accumulation, designating CD70 + CAFs as a potential new tool in anti-cancer treatment.
Results

CD70 expression and association with clinicopathological parameters
Immunohistochemical (IHC) analysis was performed to evaluate CD70 protein expression in 51 CRC tumor samples, 9 adenoma samples and 7 healthy colon specimens (Table S1 ). We found no expression of CD70 on adenoma samples and normal colon tissue. Expression of CD70 on the tumor cells could only be detected in a small subset of malignant cells in 3.9% of CRC samples. Instead, CD70 appeared to be highly abundant on CAFs in the TME of invasive cancer specimens. CD70 expression on CAFs was scored as 1+ in 13 (25.5%), 2+ in 19 (37.3%) and 3+ in 6 (11.8%) tumor specimens, as demonstrated in Figure 1A . Thereby no CD70-positive CAFs were found in normal tissue, adenoma or in situ carcinoma (T is ). As demonstrated in Figure 1B , almost all invasive tumor specimens showed CD70-positive CAFs with 84.6% of specimens staining positive (>10% CD70 + CAFs)
in T 4 N x M x stages. This could also be demonstrated when biopsies from various disease stages of the same patient were tested for the expression of CD70 (N=6). Here, CAFs showed increased positivity of CD70 with increasing TNM classification (Table S2) . Finally, CD70-expression could always be shown adjacent to the tumor cells and appeared to be more present at the invasive margin of the tumor ( Figure 1C ).
To explore clinical relevance of CD70-expressing CAFs in CRC, associations between clinicopathological characteristics and stromal CD70 expression were analysed in all patients.
Thereby, CD70 was divided into a low (10% CD70 + CAFs) (grade 0 and 1+) and high (>10% CD70 + CAFs) (grade 2+ and 3+) positive group. As described in Table 1 , stromal CD70 expression showed a significant association with strong tumor invasiveness (P<0.001), nodal invasion (P=0.006), clinical stage (P=0.001) and the presence of liver metastasis (P=0.009). In addition, CD70 expression was mostly seen in association with moderate desmoplastic reactions (P=0.005). We did not find any association between the CD70 expression level and MSI-status of the tumor.
Characterization of CD70-positive CAFs
To confirm the expression of CD70 on CAFs and to distinguish the CD70 + CAFs from other known subsets of CAFs, we examined the expression of SMA and Fibroblast-activation protein  (FAP) in 5 CRC specimens with negative (-), low (1+) and moderate (2+) CD70-positivity. As displayed in Figure 2 and 
Association of CD70 expression with Tregs
We found a significant association between high Treg amounts and high (2+, 3+) CD70 staining 
Correlations between CD70, Tregs, and survival
Follow-up data were available for all CRC patients. Twenty-one (41%) patients died during the followup period and 25 (49%) patients showed disease progression after a mean follow-up of 171 months.
Kaplan Meier analysis was used to assess overall survival (OS) and progression-free survival (PFS) probability for CD70, CD4 and Tregs ( Figure 3 shown to increase Interleukin-2 (lL-2) secretion and IL-2 is a crucial growth survival factor for nTregs 16 . Therefore, we have analysed the IL-2 protein levels and found a strong increase in IL-2 protein levels when CD70 high CAFs were present ( Figure 4D ). We have found no difference in TGF-ß production. In conclusion, our results suggest an immune evasive effect of CD70 high CAFs by increasing the survival of nTregs.
Effect of CD70-expressing CAFs on Tregs
Role of CD70-positive CAFs in migration
The aforementioned presence of CD70-positive CAFs at the invasive margin of the tumor suggests a role of these CAFs in cancer cell migration. We analysed the migratory capacities of CD70 high and CD70 low CAFs by real-time analysis of Transwell migration. Twelve hours after initiation, we observed an 8.7-fold increase in migration of the CD70 high CAFs compared to its CD70 low counterpart ( Figure   5A ). In a next set of experiments, CD70 high and CD70 low CAFs were co-cultured with CRC cells and subjected to scratch wound migration. Interestingly, CRC cells alone were not capable of spontaneously migrating towards the gap (data not shown). Instead, CAFs showed strong migratory capacities. We revealed a significant increase in migration of the CD70 high CAFs with a relative wound density of 66.033.08% compared to 28.331.72% for the CD70 low CAFs (P<0.05), 12h after wound initiation ( Figure 5B ). In summary, these data indicate the strong migratory capabilities of CD70 high CAFs.
Discussion
Numerous studies indicate that tumor progression and invasiveness are determined not only by the malignant cancer cells themselves, but also by the surrounding tumor microenvironment. We are the first study to demonstrate the expression of the immune checkpoint molecule CD70 on CAFs.
Moreover, we have found that CAF CD70-positivity was significantly associated with poor clinicopathological parameters and served as an independent prognostic marker in CRC. Finally, we revealed the potential role of CD70-positive CAFs in immune escape by the accumulation of naturally occurring Tregs and their increased migratory capacities.
Over the past years, the discovery of immune checkpoint receptors such as CTLA-4 and PD-1 introduced a new, exciting era in cancer immunotherapy. Moreover, accumulating clinical evidence points toward a promising role for checkpoint blocking antibodies in a rapidly expanding spectrum of solid tumors [17] [18] [19] [20] . However, immunotherapy in human CRC is limited to a small subset of patients with MSI-positive tumors 21, 22 . The rationale behind this observation might be the dense immune infiltrate in MSI tumors due to the increased antigenicity as well as the expression of targetable immune checkpoints such as PDL-1 21, 23, 24 . However, there also could be alternative mechanisms underlying this difference in responsiveness between MSI and MSS, such as the predominance of tumor stroma in the latter 25 . Therefore, in this report, we have not merely focused on the expression of immune checkpoint molecules by cancer cells but also taken the tumor stroma into account.
Unexpectedly, CD70 overexpression could only be strongly detected on the CAFs. Moreover, CD70 expression on CAFs acted as an independent predictor for shorter OS and PFS. In addition, CD70-positivity was correlated with adverse clinicopathological parameters and displayed no association with MSI-status, highlighting the potential of this target in CRC subsets that do not benefit from immune checkpoint blockade. 26, 27 . In our series, we found the expression of SMA as well as FAP in nearly all CAFs. On the other hand, CD70 marked a distinct subset of CAFs within these dual positive CAFs. We could also demonstrate a substantial increase in migratory capacities within CD70 high CAFs supporting our IHC data on the role of CD70 in tumor progression.
Although we are the first to describe this effect by CD70-positive CAFs, CD70 overexpression on tumor cells has already been linked with migration in non-small cell lung cancer, melanoma and glioblastoma [28] [29] [30] . In the latter, knockdown of the CD70 gene resulted in a decrease in genes associated with tumor epithelial-mesenchymal transition (EMT) such as CD44 and SOX2. Also in CRC, overexpression of CD44 has been shown to drive EMT changes 31, 32 . One other possible mechanism of action is the activation of CD70. Recently, it has been described that CD70 is not only a ligand but contains an underlying signalling cascade whereby activation leads to MAPK activation, RhoE overexpression and cytoskeletal changes, driving migration in melanoma 29 .
It has been demonstrated that targeting the CD70/CD27 axis can inhibit an effective anti-tumor immune response by three modes of action: accumulation of Tregs, T-cell apoptosis and skewing Tcell towards T-cell exhaustion 13 . Increased numbers of Tregs have been particularly found in the presence of CD70-expressing tumor cells due the expression of CD27 on the Tregs 13, 33, 34 . The interaction of CD70 and CD27 even promoted tumor growth in solid tumor-bearing mice by a decrease in Treg apoptosis and the production of IL-2, a key player in Treg survival 15 . . Consequently, our data strongly suggest a role of the CD70 pos CAFs in immune escape by the accumulation of nTregs.
Although we believe that blocking the CD70/CD27 interaction can release the effect of CD70-positive CAFs on the immune system, we don't presume this hold true for its other pro-tumorigenic effects.
Moreover, in our experiments, CD70-positive CAFs showed increased migratory capacities without the presence of CD27. Several antibodies targeting CD70 are being evaluated in clinical trials and can therefore also be beneficial to deplete CD70 + CAFs. Thereof, SGN-CD70A and MDX-1203 are antibody-drug conjugates that rely upon internalization for a toxin to exert its anti-tumor function 45, 46 . On the other hand, ARGX-110 is an anti-CD70 antibody with a complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis activity with no need for internalization, providing extra dimensions to the anti-tumor effect 47 .
Our 
Material and Methods
Patient selection and tissue specimens
Fifty-one formalin-fixed paraffin embedded (FFPE) specimens (Biobank@UZA, Antwerp, Belgium; ID:
BE 71030031000) were collected from CRC patients, of which the main characteristics are described in Table S1 48 . In addition, 9 adenoma samples and 7 healthy colon specimens were available. The average age (±SD) of the patients included in this study was 66 ± 11 years (age range 36 to 85 years).
This study was approved by the Ethics Committee of the Antwerp University Hospital. A written informed consent from all patients regarding tissue sampling has been obtained.
Immunohistochemistry
Protein expression. Tissue sections were prepared as previously described and permeabilization using the FOXP3 Transcription factor staining buffer set (Thermo Fisher Scientific). Thereafter, cells were stained for intracellular TGF- (IQ products), IL-10 (Biolegend) or FOXp3 (Thermo Fisher Scientific), acquired on a BD FACSAria II instrument (BD) and analysed using FlowJo v10.1 software ( Figure S2 ). In addition, supernatants was collected 5 days after co-culture and used to measure IL-2 protein levels (multiplexed particle-based flow cytometry cytokine assay (R&D Systems)) and TGF-ß protein levels (enzyme-linked immunosorbent assay, Thermo Fisher Scientific)
following the instructions of the manufacturer.
Transwell and Scratch Wound Migration assay
Transwell migration experiments were performed using modified 16-well plates (CIM-16, Roche) in the xCELLigence real-time cell analysis (RTCA) system with each well consisting of an upper and a lower chamber separated by a microporous membrane containing randomly distributed 8 µm-pores 53 . Initially, 160µL and 30µL of media was added to the lower and upper chambers respectively and the CIM-16 plate was locked in the RTCA DP device at 37°C for 1h to measure a background signal. The IncuCyte scratch-wound analysis software allowed for quantification of the increasing cell confluence inside the wound using the "Relative Wound Density" metric. Scratches were performed at least in triplicate and wells with inappropriate or uneven scratches were excluded from analysis.
Statistical analysis
Associations between CD70, CD4 and Treg with clinicopathological parameters of CRC patients were investigated by χ2 analysis or Fisher's exact test (when appropriate). Spearman correlation coefficients were calculated to investigate the correlation between the expression of CD70, CD4 and Tregs in CRC specimens. The prognostic value was determined by survival analysis. Thereby, PFS was defined as the time until disease progression. Overall survival OS was defined as the time until cancer related death occurred. Univariate OS and PFS probability were estimated using the Kaplan-Meier method. Statistical significance was determined using the log-rank test. Multivariate cox proportional-hazard model was assessed to identify independent prognostic markers, presented as a hazard ratio and its 95% confidence interval. For in vitro experiments, Kruskal-Wallis tests were assessed for comparisons between three groups. If significant differences were revealed, Mann-Whitney U tests were performed for pairwise comparisons. All analyses were performed using SPSS 
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